NATICK, Mass., Jan. 12 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX - News) today welcomed the results of an independent study demonstrating that Boston Scientific’s TAXUS® paclitaxel-eluting stent (PES) exhibited a lower re-intervention rate and equal or lower instances of death or heart attack than the Cypher® sirolimus-eluting stent (SES) and bare- metal stents (BMS). The results of the study were published in the January 1 edition of the European Heart Journal.
